Conformation-Specific TNFα Antibody Epitopes for Complex Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antagonists of TNF superfamily members, such as anti-TNFα antibodies and soluble TNFα receptor fusion proteins, are macromolecular and inhibit binding to receptors, lacking specificity and efficacy in modulating TNFα signaling.
Innovation Solution
Development of small molecular entities (SMEs) that bind to the homotrimeric form of TNFα, inducing conformational changes and stabilizing the trimer, and antibodies that selectively recognize these complexes to identify and modulate TNFα signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antagonists (anti-TNFα antibodies, soluble TNFα receptor fusion proteins) are used, then TNFα binding to receptors is inhibited, but the antagonists are macromolecular and lack specificity in modulating TNFα signaling
Solution Approach 1:
The invention extracts and stabilizes the active homotrimeric form of TNFα using small molecular entities, separating this specific conformational state from the complex macromolecular antagonists. The SMEs specifically bind to and stabilize the homotrimer, enabling selective modulation of TNFα signaling without requiring large antibody or fusion protein structures.
Solution Approach 2:
The invention changes the molecular size parameter from macromolecular (antibodies, fusion proteins) to small molecular entities. This parameter change enables improved specificity in modulating TNFα signaling while maintaining the ability to inhibit receptor binding, as the SMEs can precisely target the homotrimeric conformation.
2Reliability
If small molecular entities are developed to bind TNFα and induce conformational changes, then specificity and efficacy in modulating TNFα signaling is improved, but the ability to selectively identify and screen for such compounds becomes more difficult
Solution Approach 1:
The invention introduces conformation-specific antibodies as intermediary detection tools. These antibodies specifically recognize and bind to the homotrimeric TNFα conformation stabilized by SMEs, serving as a mediator that enables easy detection and screening of compound-TNFα complexes. This intermediary approach transforms the difficult task of directly detecting small molecule binding into a simple antibody-based assay.
3Adaptability or versatility
If conventional macromolecular antagonists are used, then TNFα receptor binding is inhibited, but therapeutic options for TNFα-mediated conditions are limited
Solution Approach 1:
The invention extracts the essential therapeutic function from macromolecular antagonists by isolating the key mechanism: stabilization of the homotrimeric TNFα conformation. By using small molecular entities instead of large antibodies or fusion proteins, the invention creates more versatile therapeutic options that can be optimized for different TNFα-mediated conditions while maintaining simplicity.
Solution Approach 2:
The invention changes the molecular weight and structural complexity parameters from macromolecular to small molecular scale. This enables improved adaptability and versatility in therapeutic applications, as SMEs can be more easily optimized, modified, and combined for different TNFα-mediated conditions while maintaining high specificity and efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SMEs and antibodies effectively modulate TNFα signaling by stabilizing or enhancing receptor binding, reducing downstream signaling, and providing targeted therapeutic options for TNFα-mediated conditions.
Implementation Method 1
These compounds act by binding to the homotrimeric form of TNFα, and inducing and/or stabilising a conformational change in the homotrimer of TNFα
Implementation Method 2
an antibody which binds to an epitope comprising at least the following residues of trimeric TNFα
Data Source
AI summary
It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.